Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Jul 28;14(28):4576-9.
doi: 10.3748/wjg.14.4576.

Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis

Affiliations
Case Reports

Cerebral venous thrombosis and heparin-induced thrombocytopenia in an 18-year old male with severe ulcerative colitis

Gudrun Scheving Thorsteinsson et al. World J Gastroenterol. .

Abstract

The risk of thromboembolism is increased in inflammatory bowel disease and its symptoms may be overlooked. Furthermore, its treatment can be complex and is not without complications. We describe a case of an adolescent boy who developed a cerebral sinus venous thrombosis during a relapse of his ulcerative colitis and who, while on treatment with heparin, developed heparin-induced thrombocytopenia (HIT). The treatment was then switched to fondaparinux, a synthetic and selective inhibitor of activated factor X.

PubMed Disclaimer

Figures

Figure 1
Figure 1
T1 contrast enhanced transverse image showing a focal dark area (arrow) in the right transverse sinus and confluence, which are consistent with a cerebral sinus thrombosis.
Figure 2
Figure 2
Platelet count expressed in 109/L blood (normal range, 125-340) from readmission until discharge showing the progress of thrombocytopenia. The letters denote start or end of heparin (Hs and He), fondaparinux (Fs and Fe), warfarin (Ws), and azatioprine (Ae and As). W1 denotes only one dose. Dotted line denotes a level of thrombocytes lower than their normal range.

References

    1. Sawczenko A, Sandhu BK, Logan RF, Jenkins H, Taylor CJ, Mian S, Lynn R. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet. 2001;357:1093–1094. - PubMed
    1. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006;(2):CD000543. - PubMed
    1. Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut. 2006;55:437–441. - PMC - PubMed
    1. Ozdil S, Akyuz F, Pinarbasi B, Demir K, Karaca C, Boztas G, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, et al. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?) Hepatogastroenterology. 2004;51:768–770. - PubMed
    1. Masuhr F, Mehraein S. Cerebral venous and sinus thrombosis: patients with a fatal outcome during intravenous dose-adjusted heparin treatment. Neurocrit Care. 2004;1:355–361. - PubMed

Publication types